Kimia Biosciences receive approval to manufacture new API

Research and development (R&D) driven integrated pharmaceutical company, Kimia Biosciences Ltd, announced that it has bagged permission for manufacturing and marketing of Azelnidipine API.

In a regulatory filing made on Wednesday after the market hours, the company informed that it has been granted permission for manufacturing and marketing of a new active pharmaceutical ingredient (API), i.e. Azelnidipine drug.

Kimia Biosciences added that the approval has been given by Central Drugs Standard Control Organisation (CDSCO), which is the national regulatory body for Indian pharmaceuticals and medical devices, functioning under Directorate General of Health Services.

Earlier known as Laurel Organics, the name of the company was changed to Kimia Biosciences, with effect from January 4, 2019. The company is engaged in the manufacturing of bulk drugs, addressing to various high potential therapeutic segments. Kimia Biosciences have been awarded with good manufacturing practice (GMP) certification by World Health Organisation (WHO).

At 9.22 am on Thursday, the stock of Kimia Biosciences Ltd is trading at Rs 24.90, up by 4.84 per cent against its previous close of Rs 23.75. Its 52-week high is Rs 35.00 while, its 52-week low is Rs 19.05 on BSE.